43.16
-1.74 (-3.88%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Enliven Therapeutics, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 2.0 |
| 内部交易活动 | -1.5 |
| 价格波动 | -3.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 2.5 |
| 平均 | 0.50 |
|
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven’s programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 4.75% |
| 机构持股比例 | 90.86% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Fairmount Funds Management Llc | 31 Dec 2025 | 3,711,444 |
| Novo Holdings A/S | 31 Dec 2025 | 1,480,000 |
该时间范围内无数据。
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| COLLINS HELEN LOUISE | - | 48.11 | -5,000 | -240,550 |
| 累积净数量 | -5,000 | |||
| 累积净值 ($) | -240,550 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 48.11 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| COLLINS HELEN LOUISE | 职员 | 17 Apr 2026 | 自动卖出 (-) | 5,000 | 48.11 | 240,550 |
| COLLINS HELEN LOUISE | 职员 | 17 Apr 2026 | 执行期权 | 5,000 | - | - |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合